Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
fda
biotech
boston blog main
boston top stories
national top stories
new york blog main
abbvie
amgen
detroit blog main
detroit top stories
eli lilly
national
new york top stories
parkinson's disease
paul matteis
san diego blog main
san diego top stories
acorda therapeutics
acute hepatic porphyrias
akin akinc
alder biopharmaceuticals
allergan
alnylam pharmaceuticals
aminolevulinic acid
ampyra
apokyn
apomorphine
bempedoic acid
bial
biohaven
boston
boulder/denver blog main
boulder/denver top stories
calcitonin gene-related peptide
cgpr
cholesterol
chronic migraine
What
fda
6
×
nod
6
×
drug
approved
gets
medicines
new
pill
approval
class
disease
migraine
parkinson’s
patients
second
treatment
wins
acorda
add
adults
ago
allergan
alnylam
amgen
called
candidates
carbidopa
cholesterol
combination
combo
control
cope
daily
developed
episodes
esperion
esperion’s
experience
friday
head
Language
unset
Current search:
nod
×
fda
×
@xconomy.com
3 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
4 years ago
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines